To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and
GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to …

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Over the past two decades, bile acids (BAs) have become established as important
signaling molecules that enable fine-tuned inter-tissue communication from the liver, their …

Abstract Aims/Introduction Previous studies have reported that the glucagon‐like peptide‐1
receptor agonist (GLP‐1RA) delays gastric emptying, and gastric emptying was assessed by …

Purpose Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide are a
class of medications prescribed to treat type 2 diabetes mellitus, and more recently, as an …

Unimolecular triple incretins, combining the activity of glucagon-like peptide-1 (GLP-1),
glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG), have …

The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …

Objective This study aimed to determine the effects of a long‐acting glucagon‐like peptide‐1
(GLP‐1) receptor agonist, liraglutide, and placebo subcutaneously over 16 weeks on weight …